Hydventia

Hydrocortisone, the active ingredient in Hydventia, is a corticosteroid (glucocorticoid) presented as a oral tablet for oral use. It replaces deficient cortisol in adrenal insufficiency and reduces inflammation in a range of autoimmune and inflammatory disorders.

GNH USA supplies Hydventia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydrocortisone acts on the glucocorticoid pathway to manage endocrine deficiency and inflammatory disease.

- Addison's disease (adrenal insufficiency): restores physiologic cortisol levels and prevents adrenal crisis. - Rheumatoid arthritis: diminishes joint inflammation and pain, improving mobility. - Systemic lupus erythematosus: suppresses immune over‑activity to control disease flares. - Asthma exacerbations: reduces airway inflammation, aiding symptom relief. - Inflammatory bowel disease: controls intestinal inflammation during flare‑ups.

Hydrocortisone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Increased appetite and weight gain. - Fluid retention leading to mild edema. - Elevated blood glucose levels. - Insomnia or mood changes.

Serious or Rare Side Effects: - Adrenal insufficiency on abrupt discontinuation. - Severe infections due to immunosuppression. - Osteoporosis and increased fracture risk. - Cushingoid appearance, hypertension, or psychosis.

Before initiating Hydventia, clinicians should consider several safety measures.

- Monitor blood glucose: patients with diabetes may require dose adjustments. - Assess infection risk: avoid use in active systemic infections unless benefits outweigh risks. - Evaluate bone health: long‑term therapy can accelerate osteoporosis. - Taper therapy: discontinue gradually to prevent adrenal crisis. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Hydrocortisone can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Ketoconazole (CYP3A4 inhibitor): may raise hydrocortisone plasma levels. - Rifampin (CYP3A4 inducer): can reduce hydrocortisone effectiveness. - Anticoagulants such as warfarin: increased risk of bleeding.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened risk of gastrointestinal ulceration. - Antidiabetic agents: may need dose modification due to hyperglycaemia. - ACE inhibitors: potential for fluid retention and hypertension.